Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 770 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | March 07, 2015

In Case You Missed It, This New Cancer Care Cost Study Is Extremely Disappointing

We'd like to think that the billions of dollars being spent annually on cancer drug development are making a sizable impact on the lives of cancer patients. But, that may not be the case, according to this latest study.

Investing | March 06, 2015

3 Big Pharma Stocks to Buy in March

Our experts weigh in.

Investing | February 28, 2015

Which Cancer Immunotherapy Will Be the Most Successful?

Motley Fool experts discuss whether Bristol-Myers Squibb's Opdivo or Merck & Co.'s Keytruda will be the bigger commercial success.

Investing | February 23, 2015

Why Shares of Rigel Pharmaceuticals Inc. Exploded Today

Is this meaningful or just another movement?

Investing | February 16, 2015

Deal-Hungry Pfizer Won't Stop With Hospira; Who Could Be Next?

Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.

Investing | February 15, 2015

Forget Traditional Chemotherapy! Could 3D Vaccines Eventually Cure Cancer?

Utilizing the body's immune system to help fight cancer is among the latest techniques researchers are using. However, this team of researchers has developed a truly unique new way of combating cancer.

Investing | February 14, 2015

Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer

Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.

Investing | February 07, 2015

3 Drugs That Could Become Blockbusters in 2015

Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.

Investing | February 07, 2015

3 Blockbuster Drugs That May Be Obsolete in 5 Years

Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.

Investing | February 04, 2015

5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know

Bristol-Myers Squibb this week held a conference call to discuss its fourth-quarter and full-year results. Here are five things management wants investors to know.

Results 11 - 20 of 770 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY